Applicant, as named in the Orange Book

Biogen Us

Next listed expiry: Skyclarys on 24 Apr 2033. 1 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Skyclarys omaveloxolone	omaveloxolone	216718	24 Apr 2033	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.